Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 844-852 , July 2007

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow Donor Program

Received 15 February 2007 ,Accepted 25 March 2007.

References 

  1. Szydlo R, Goldman J, Klein J, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA identical siblings. J Clin Oncol. 1997;15:1767–1777
  2. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1998;338:962–968
  3. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donor for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–968
  4. McGlave P, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years experience of the National Marrow Donor Program. Blood. 2000;95:2219–2225
  5. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536
  6. Giralt S, Thall PK, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  7. Slavin S, Nagler A, Naperstak E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  8. Khouri IF, Keating M, Korbling M, et al. Transplant lite: induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817–2824
  9. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high dose cytotoxic therapy with graft versus tumor effects. Blood. 2001;97:3390–3400
  10. Ferrara JL. Pathogenesis of acute graft versus host disease: cytokines and cellular effectors. J Hematother Stem Cell Res. 2000;9:299–306
  11. Anagnostopoulos A, Giralt S. Update on nonmyeloablative stem cell transplantation for hematologic malignancies. Curr Opin Organ Transplant. 2003;8:118–124
  12. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316
  13. Niederwieser D, Maris M, Shizuru J, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620–1629
  14. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071–1078
  15. McCullough J, Hansen J, Perkins H, Stroncek D, Bartsch G. Establishment of the National Bone Marrow Donor Registry. In:  Gale RP,  Champlin RE editor. Bone Marrow Transplantation: Current Controversies, Vol 91 of UCLA Symposia on Molecular and Cellular Biology. New York: Alan Liss; 1989;p. 641–658
  16. Champlin R, Khouri I, Kornblau S, Molldrem , Giralt S. Reinventing bone marrow transplantation (Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect). Oncology. 1999;13:621–628
  17. Hall EJ, Astor M, Bedford J, et al. Basic radiobiology. Am J Clin Oncol. 1988;11:220
  18. Moreau P, Fiere D, Bezwoda WR, et al. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol. 1997;15:660–666
  19. Brodsky RA, Chen AR, Brodsky I, Jones RJ. High-dose cyclophosphamide as salvage therapy for severe aplastic anemia. Exp Hematol. 2004;32:435–440
  20. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828
  21. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man (A long-term clinicopathologic study of 20 Seattle patients). Am J Med. 1980;69:204–217
  22. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  23. Mantel consideration. Cancer Chemother Rep. 1966;60:163–170
  24. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187
  26. Antin J, Childs R, Filipovich A, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings. Biol. Blood Marrow Transplant. 2001;7:473–485
  27. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant. 2002;29:191–195
  28. Loberiza F. Report on the state of the art in blood and marrow transplantation (Part 1 of the IBMTR/ABMTR summary slides with guide). IBMTR/ABMTR Newslett. 2003;10:7–10
  29. Ballen KK, King R, Carston M, et al. Outcome of unrelated transplants in patients with multiple myeloma. Bone Marrow Transplant. 2005;35:675–681
  30. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol. 1996;14:572–578
  31. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26:397–404
  32. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021–2030
  33. Schmitz N, Bacigalupo A, Hasenclever D, et al. Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:995–997
  34. Champlin RE, Schmitz N, Horowitz MH, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95:3702–3709
  35. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–181
  36. Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999;94:455–464
  37. Remberger M, Ringdén O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001;98:1739–1745
  38. Stem Cell Trialists Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–5087
  39. de Lima M, Anagnostopoulos A, Munsell M, et al. Non-ablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome (Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation). Blood. 2004;104:865–872
  40. Diaconescu R, Flowers C, Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood. 2003;102:abst #261
  41. Shahjahan M, Alamo J, Delima M, et al. Impact of comorbidity on the outcome of allogeneic hematopoietic stem cell transplantation in AML/MDS patients. Blood. 2003;102:abst #2621
  42. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs non myeloablative allogeneic transplantation for patients with myelodysplastic syndromes or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135

PII: S1083-8791(07)00217-0

doi: 10.1016/j.bbmt.2007.03.011

Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 844-852 , July 2007

Article Tools

* Image Usage & Resolution